Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6277796 | 0.90 | CYP3A4 (0.62) | CYP3A4CYP1A2CYP2C9MEN1GAA | |
| SCHEMBL6282558 | 0.90 | CYP3A4 (0.62) | CYP3A4CYP1A2CYP2C9MEN1GAA | |
| SCHEMBL6280762 | 0.90 | CYP3A4 (0.54) | CYP3A4CYP1A2CYP2C9MEN1GAA | |
| SCHEMBL14087056 | 0.89 | CYP3A4 (0.60) | CYP3A4CYP1A2CYP2C9MEN1KMT2A | |
| SCHEMBL6282552 | 0.89 | CYP3A4 (0.60) | CYP3A4CYP1A2CYP2C9MEN1KMT2A | |
| SCHEMBL6284357 | 0.87 | CYP3A4 (0.69) | CYP3A4CYP1A2CYP2C9MEN1KMT2A | |
| SCHEMBL6286044 | 0.87 | CYP3A4 (0.69) | CYP3A4CYP1A2CYP2C9MEN1KMT2A | |
| SCHEMBL4864478 | 0.86 | CYP3A4 (0.51) | CYP3A4CYP1A2CYP2C9MEN1KMT2A | |
| SCHEMBL4865258 | 0.86 | CYP3A4 (0.51) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4867368 | 0.86 | CYP3A4 (0.51) | CYP3A4CYP1A2CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849632-B2 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ZABLOCKI JEFF (US) | 2004-09-30 | — | — | US | disclosed |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | CYP3A4 2560/4885CYP1A2 1483/4885CYP2C9 2055/4885 |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | CYP3A4 2560/4885CYP1A2 1483/4885CYP2C9 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.